Paul Berns - Jazz Pharmaceuticals Insider

Jazz Pharmaceuticals Public Limited Company -- USA Stock  

USD 154.67  0.16  0.10%

Independent Director

Mr. Paul L. Berns is an Independent Director of Jazz Pharmaceuticals PLC. Mr. Berns has served as a member of our board of directors since the closing of the Azur Merger in January 2012 and was a director of Jazz Pharmaceuticals, Inc. from 2010 until the closing of the Azur Merger. Mr. Berns is a consultant to the pharmaceutical industry. From March 2014 to June 2016, he served as the Chief Executive Officer and President of Anacor Pharmaceuticals, Inc., a biopharmaceutical company, which was acquired by Pfizer Inc. in June 2016. He also served as a member of the board of directors of Anacor Pharmaceuticals, Inc. from 2012 until 2016, including as Chairman of its board of directors from 2013 until 2016. From September 2012 to March 2014, he was a selfemployed consultant to the pharmaceutical industry. From March 2006 to September 2012, he served as President and Chief Executive Officer, and as a member of the board of directors, of Allos Therapeutics, Inc., a pharmaceutical company acquired by Spectrum Pharmaceuticals, Inc. From July 2005 to March 2006, Mr. Berns was a selfemployed consultant to the pharmaceutical industry. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporationrationration in 2005. From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories, a pharmaceutical company. From 2000 to 2001, he served as Vice President, Marketing of BASF PharmaceuticalsKnoll, a pharmaceutical company, and from 1990 to 2000, Mr. Berns held various positions, including senior management roles, at BristolMyers Squibb Company, a pharmaceutical company
Age: 49  Director Since 2010      
353 1 634 7800  http://www.jazzpharma.com
Berns received a B.S. in Economics from the University of Wisconsin. With his experience as Chief Executive Officer of Allos Therapeutics, Inc., Anacor Pharmaceuticals, Inc. and Bone Care International Inc., and his experience serving

Paul Berns Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 7.73 % which means that it generated profit of $7.73 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 21.25 % meaning that it created $21.25 on every $100 dollars invested by stockholders.
The company currently holds 1.58 B in liabilities with Debt to Equity (D/E) ratio of 58.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Jazz Pharmaceuticals Public Limited Company has Current Ratio of 3.22 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

William KaelinEli Lilly and Company
2012
Catherine KlemaAllergan plc
2016
Michael GallagherAllergan plc
2015
Vicki SatoBristol Myers Squibb Company
2017
Rochelle LazarusMerck Co
2004
Joseph BoccuziAllergan plc
2017
Patricia RussoMerck Co
1995
Jose BaselgaBristol Myers Squibb Company
2018
Gerald StorchBristol Myers Squibb Company
2012
Louis DrapeauBio Rad Laboratories
2007
Peter WendellMerck Co
2003
Todd SisitskyEndo International plc
2016
David CarlucciMallinckrodt Public Limited Com
2013
Nancy McKinstryAbbott Laboratories
2011
Diane GulyasMallinckrodt Public Limited Com
2013
Pamela CraigMerck Co
2015
Kneeland YoungbloodMallinckrodt Public Limited Com
2013
Margaret McGlynnVertex Pharmaceuticals Incorpor
2011
Karen HornEli Lilly and Company
2012
Leslie BrunMerck Co
2016
Jack GreenbergIQVIA Holdings
2016

Entity Summary

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. In addition, it evaluates deuterated oxybate for narcolepsy and sells psychiatry and other products. Jazz Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 1210 people.Jazz Pharmaceuticals Public Limited Company (JAZZ) is traded on NASDAQ in USA. It is located in IRELAND and employs 1,210 people. Jazz Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Jazz Pharmaceuticals Leadership Team

Matthew Young, CFO, MBA
Paul Berns, Director
Iain McGill, President
Daniel Swisher, President, MBA
Suzanne Hooper, EVP
Rick Winningham, Director, MBA
Peter Gray, Director
Heather McSharry, Director
Michael Miller, SVP, MBA
Katherine Littrell, President
Paul Treacy, President
Patrick Enright, Director, MBA
Karen Wilson, President
Norbert Riedel, Director, Ph.D
Seamus Mulligan, Director
Russell Cox, COO
Catherine Sohn, Director
Karen Smith, Executive, MBA
Elmar Schnee, Director
Kenneth OKeefe, Director, MBA
Bruce Cozadd, Chairman, MBA

Stock Performance Indicators

Current Sentiment - JAZZ

Jazz Pharmaceuticals Investor Sentiment
Most of Macroaxis users are currently bullish on Jazz Pharmaceuticals Public Limited Company. What is your judgment towards investing in Jazz Pharmaceuticals Public Limited Company? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Generate Optimal Portfolios

Align your risk and return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.